Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,966 JPY | +2.96% | +0.85% | -7.04% |
May. 14 | Japan's Nikkei drifts sideways as more earnings, US CPI awaited | RE |
May. 01 | Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With a 2024 P/E ratio at 22.97 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.04% | 51.25B | A- | ||
+35.01% | 709B | C+ | ||
+30.58% | 595B | B | ||
-2.60% | 367B | C+ | ||
+20.83% | 334B | B- | ||
+5.69% | 289B | C+ | ||
+13.96% | 239B | B+ | ||
+9.23% | 211B | B- | ||
-3.39% | 203B | A+ | ||
+10.77% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4519 Stock
- Ratings Chugai Pharmaceutical Co., Ltd